The Ipamorelin studies asked different questions.

The early hormone experiments tested animal cells, rats and pigs. Ipamorelin released growth hormone without the same rise in ACTH and cortisol seen with some older peptides. Those two hormones help the body respond to stress.

That’s where the selectivity description comes from. It’s a comparison of hormone responses in animals. It wasn’t a test of human sleep, exercise recovery or long-term health.

I keep that boundary visible because the finding is interesting enough on its own. It doesn’t need an extra benefit attached to earn its place.

In the human hormone-response study, healthy men received infusions into a vein. Researchers measured Ipamorelin in the blood and a short-lived rise in growth hormone. They learned about how it behaved under those conditions.

The study didn’t show that people felt or functioned better. The FDA review also didn’t find human data on blood levels or hormone response after the proposed injection under the skin. The route stays part of the finding.

The published bowel-surgery trial asked whether Ipamorelin could help gut function recover after an operation. Its main measure was time to the first tolerated meal. That comparison with placebo wasn’t statistically significant. Placebo means the comparison treatment without the active ingredient.

I don’t turn that into “it can never help anyone”. I also don’t let a promising mechanism turn a negative main result into a positive one. The trial tested a particular treatment question in a hospital.

Serious events occurred in both groups. FDA discusses two deaths after complications of cancer surgery in people given Ipamorelin. Its review leaves the compound’s role unclear; it neither establishes causation nor rules it out.